The global structural biology and molecular modeling techniques market is experiencing robust expansion, with its valuation estimated at US$5.9 billion in 2025 and projected to grow to US$18 billion by 2032. According to a recent industry report added to ResearchAndMarkets.com, this growth represents a compound annual growth rate (CAGR) of 17.3% across the forecast period from 2025 through 2032. Market expansion is being propelled by rising global demand for precision medicine, targeted drug discovery, protein engineering, and advanced disease research.
Technological advancements are central to this trajectory, with methods such as X-ray crystallography, nuclear magnetic resonance spectroscopy, cryo-electron microscopy (cryo-EM), and computational modeling providing critical molecular insights. X-ray crystallography currently holds a leading market position due to its established role in high-resolution biomolecular analysis. Meanwhile, cryo-EM is gaining prominence as improvements in imaging resolution and analytical workflows expand its utility across complex proteins and molecular assemblies. Furthermore, faster computing infrastructure, machine learning algorithms, and sophisticated visualization platforms are enhancing both the speed and accuracy of computational modeling.
Drug discovery remains a primary application segment, driven by the necessity to formulate more selective and effective therapies. Structural analysis enables rational drug design and structure-based optimization, while computational modeling aids in predicting drug-target interactions and assessing molecular modifications prior to laboratory testing. Protein engineering also stands out as a key growth area, utilizing modeling platforms to modify proteins and enzymes for improved stability, activity, and specificity in biopharmaceuticals and industrial enzymes. Additionally, structural biology contributes to genomics and disease research by uncovering how genetic mutations affect protein structure and function.
Pharmaceutical and biotechnology companies, alongside academic institutions and research institutes, represent the major end users of these technologies. Geographically, the market analysis spans the United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The U.S. market stood at US$1.6 billion in 2025. China is anticipated to record a notable CAGR of 22.4%, reaching approximately US$4.1 billion by 2032. Within tool categories, the Software-as-a-Service (SaaS) and standalone modeling segment is forecast to hit US$10.6 billion by 2032 at a CAGR of 18.3%, while the databases segment is projected to expand at a CAGR of 15.5%.
Featured entities mentioned within the market research scope include Agilent Technologies, Inc., Bruker Daltonics Inc., Dassault Systemes, Illumina, Acellera Ltd., Affymetrix, Agile Molecule, Bioinformatic LLC, Biomax Informatics AG, Chemical Computing Group, and CLC bio.
